ibusinesslines.com December 18, 2018

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) declared EPS of

27 April 2017, 04:04 | Kelvin Horton

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares have been recently spotted -45.95% away from the 52-week high, and 330.54% away from the 52-week low mark.

Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms. Oppenheimer Holdings analyst H. Singh now expects that the biotechnology company will earn $3.49 per share for the year, up from their previous forecast of $3.48.

In a statement issued on 04/24/2017 Vetr Inc. upped the price target of Sarepta Therapeutics Inc (NASDAQ:SRPT) to $37.67 stating a potential upside of 0.11%. Cowen and Company reaffirmed an outperform rating and set a $62.00 price objective on shares of Sarepta Therapeutics in a research report on Saturday, March 11th.

03/01/2017 - Sarepta Therapeutics, Inc. had its "buy" rating reiterated by analysts at Needham & Company. National Bank Of America De reported 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). The stock has "Neutral" rating by Piper Jaffray on Friday, January 15. Finally, Nomura initiated coverage on shares of Sarepta Therapeutics in a research report on Wednesday, March 1st. They set a buy rating and a $84.00 price objective on the stock. Out of 24 Wall Street analysts rating Sarepta Therapeutics, 16 give it "Buy", 1 "Sell" rating, while 7 recommend "Hold".

The stock's price switched up 18.58% 20-Days Simple Moving Average, added 17.66% from 50-Days Simple Moving Average and rose 5.99% from 200 Days Simple Moving Average. The overall volume in the last trading session was 3.28 million shares. The company has market cap of 2.06 billion GBP. Ameriprise Fincl reported 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). The analysts estimated EPS for the higher end at -0.55 and lower end at -1.34 while the year ago reported earnings per share was -0.8.

14 number of analysts have estimated the sales of the company for the quarter ending April 27, 2017, analysts estimated mean sale target of 27.08 million while high and low sale targets are estimated at 37.82 million and 20.17 million respectively. The business's quarterly revenue was up 333.6% compared to the same quarter previous year. During the same period in the prior year, the company posted ($1.44) EPS.

COPYRIGHT VIOLATION WARNING: This story was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & worldwide trademark & copyright law. The original version of this article can be accessed at https://transcriptdaily.com/2017/04/23/sarepta-therapeutics-srpt-outperform-rating-reaffirmed-at-robert-w-baird.html. If the average volume is low then the liquidity is low which means it is hard to buy or sell the stock as there are fewer buyers or sellers of the stock.

03/01/2017 - Instinet began new coverage on Sarepta Therapeutics, Inc. giving the company a "buy" rating. Jennison Associates LLC now owns 1,393,788 shares of the biotechnology company's stock worth $85,593,000 after buying an additional 647,030 shares in the last quarter. BlackRock Advisors LLC now owns 839,928 shares of the biotechnology company's stock worth $51,580,000 after buying an additional 697,122 shares in the last quarter. Lehman Financial Resources Inc. bought a new stake in Sarepta Therapeutics during the third quarter worth approximately $237,000. Investors have the ability to follow analyst projections in order to help compile valuable company information.

Sarepta is a biopharmaceutical company focused on the discovery and development of therapeutics for the treatment of rare, infectious and other diseases. The Company developed the drug eteplirsen for the treatment of Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease.

Other News

Trending Now

Topshop's Clear Plastic Jeans Are Here
It's been a week of freakish options becoming available in the fashion industry: first $425 muddy jeans from Nordstrom and now. And despite their $100 price tag, the clear, straight leg jeans are now listed as out of stock on the company's website.

Senators Briefed on 'Grave' North Korean Threat
A US guided-missile submarine also docked in South Korea this week. "We remain open to negotiations to towards that goal". He dismissed North Korea's threats to sink the aircraft carrier and its strike group, saying "if it flies, it will die".

Trump agrees to renegotiate NAFTA with Canada, Mexico leaders
Under the joint treaty, US trade along with the two countries have supported over 140,000 small to medium sized businesses. The softwood spat is unfolding amid a much bigger trade issue — renegotiation of the North American Free Trade Agreement.

'Better Than Anticipated': Trump on Results of Tillerson's Visit to Russian Federation
Rex Tillerson and Sergei Lavrov met in Moscow on Wednesday. "There is a low level of trust between our two countries", he said. Never mind that Obama ultimately agreed with Trump about the risks of involving the U.S.in yet another Middle Eastern war.

Louis wins U.S. approval to explore airport privatization
The 16-year-old SUV driver and two 15-year-old passengers were taken to a hospital with non-life-threatening injuries. The officer gave chase and the SUV exited at the airport, striking a auto containing two women and two children.

Leicester 1-1 Atletico: Reaction from Craig Shakespeare
Their battling display against Atletico, who prevailed 2-1 on aggregate after a 1-1 draw on Tuesday, won them universal praise. Atletico were now content to start counting down the minutes but Leicester refused to accept their journey was nearly over.

President Trump's daughter Ivanka defends his attitude towards women
He was also publicly ridiculed for appearing to refuse to shake Merkel's hand when she met with him at the White House in March. The audience booed and hissed at her when she defended her father's attitudes towards women during a discussion on paid leave.